Go or no go? Esperion's double whammy and a look to priority reviews
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
